Christopher P. Molineaux

CIK: 0001654773

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (33.3%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRS

Aclaris Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ACRS
Aclaris Therapeutics, Inc.
Jun 5, 2026
Exercise(M)
Direct
11.6K shares-
ACRS
Aclaris Therapeutics, Inc.
Jun 4, 2026
Award(A)
Stock Option (Right to Buy)
Direct
42.4K shares-
ACRS
Aclaris Therapeutics, Inc.
Jun 4, 2026
Award(A)
Restricted Stock Units
Direct
11K shares-
ACRS
Aclaris Therapeutics, Inc.
Jun 6, 2025
Exercise(M)
Direct
4.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Jun 5, 2025
Award(A)
Stock Option (Right to Buy)
Direct
42.4K shares-
ACRS
Aclaris Therapeutics, Inc.
Jun 5, 2025
Award(A)
Restricted Stock Units
Direct
11.6K shares-

		Type	Shares	Price		Ownership
Jun 5, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	11,580	-	$0	Direct
Jun 4, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	42,350	-	-	Direct
Jun 4, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	10,987	-	-	Direct
Jun 6, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	4,793	-	-	Direct
Jun 5, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	42,350	-	-	Direct
Jun 5, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	11,580	-	-	Direct

1-6 of 6 transactions

About Molineaux Christopher P.

Molineaux Christopher P. (SEC CIK 0001654773) files insider reports with the SEC as Director of Aclaris Therapeutics, Inc. (ACRS).

Signal8 holds 2 ownership filings by Molineaux Christopher P., all Form 4s, filed between Jun 9, 2025 and Jun 8, 2026. Those filings report 6 transactions, from Jun 5, 2025 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Molineaux Christopher P.'s filings is in WAYNE, PA.

Recent filings by Molineaux Christopher P.

Jun 5, 2026: Option exercise of ACRS shares (Form 4, code M).
Jun 4, 2026: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).
Jun 6, 2025: Option exercise of ACRS shares (Form 4, code M).
Jun 5, 2025: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).

Other insiders filing for Aclaris Therapeutics, Inc. (ACRS)

Kolbeck Roland Wilhelm, Chief Scientific Officer
SCHIFF ANDREW N, Director
Mehra Anand, Director
Humphries William D., Director
MILANO VINCENT, Director
GOWEN MAXINE, Director

How to read Form 4 transaction codes